Decsa-TRV belongs to the group of synthetic glucocorticosteroids and has a potent anti-inflammatory, desensitizing effect and immunosuppressive activity.
Dexamethasone - a synthetic glucocorticosteroid (GCS), a methylated derivative of fluoroprednisolone, increases the sensitivity of beta-adrenergic receptors to endogenous catecholamines.
The mechanism of action of the hormone is to block the release of inflammatory mediators by eosinophils, including prostaglandins, which potentiate the inflammatory process, stimulate the biosynthesis of lipocortin with anti-oedematous activity, reduce the number of mast cells that produce hyaluronic acid, and reduce capillary permeability.
The main effect of dexamethasone on metabolism is associated with protein catabolism, an increase in gluconeogenesis in the liver, and a decrease in glucose disposal by peripheral tissues.
With parenteral administration of dexamethasone, the maximum plasma concentration is detected after 60 minutes. The therapeutic concentration in blood serum lasts up to 48 hours, depending on the type of animal. It is excreted from the body mainly with urine and bile. The bioavailability of dexamethasone when administered intramuscularly is 100%.
Decsa-TRV, according to the exposure degree to the body, is classified as low-hazard substances (hazard class 4 according to GOST 12.1.007-76).